Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular A… (NCT05205005) | Clinical Trial Compass
CompletedPhase 2/3
Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes
United States24 participantsStarted 2022-05-25
Plain-language summary
The prevalence of type 2 diabetes (T2D) continues to increase in the US, with 26.8 million adults carrying a diagnosis. Importantly, T2D is widespread in the Veteran population. This epidemic of T2D also contributes to the staggering rates of cardiovascular disease and cardiovascular mortality. Lifestyle modifications, including increased physical activity, are recommended as first-line therapy for the management of T2D. Unfortunately, patients with T2D exhibit diminished vascular adaptations to exercise. The proposed project will test the overall hypothesis that degradation of the endothelial glycocalyx, a characteristic feature of T2D, precludes shear stress mechanotransduction and consequent exercise-induced vascular adaptations. As such, the investigators pose that restoration of the endothelial glycocalyx via dietary supplementation of glycocalyx precursors will potentiate vascular adaptations to exercise in Veterans with T2D.
Who can participate
Age range45 Years – 64 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. 45-74 years of age at the time of enrollment
✓. Diagnosis of T2D by a health care provider, confirmed by chart review
✓. HbA1c \<9% and fasting blood glucose \<200 mg/dL at screening visit
✓. Body mass index (BMI) 25-45 kg/m2
✓. Women should be postmenopausal (absence of menses for at least 1 year)
✓. Sedentary subjects (\<2 days/week of vigorous exercise)
✓. Willingness to follow up instructions provided by study team
Exclusion criteria
✕. Evidence of cardiac arrhythmias, unstable angina (or other cardiac event), heart failure or stroke in the last 12 months
✕. Evidence of chronic kidney disease stage IV or V (GFR \<30 mL/min)
✕. Evidence of uncontrolled hypertension, systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 110 mmHg on more than 2 occasions in the past 12 months or at screening visit
What they're measuring
1
Glygocalyx Integrity - Perfused Boundary Region
Timeframe: Change from baseline to eight weeks assessment